515 Eastern Avenue
586 articles with Perrigo Company
Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.19 per share, payable on March 19, 2019 to shareholders of record on March 1, 2019.
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that it will release its fourth quarter and calendar year 2018 financial results on Wednesday, February 27, 2019. The Company will host a conference call beginning at 4:30 p.m. (EST).
Perrigo Announces Patent Litigation Settlement for the Generic Version of Jublia® Topical Solution 10%
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that it has settled its Hatch-Waxman litigation relating to its first-to-file Abbreviated New Drug Application for the generic equivalent to Jublia® (efinaconazole) Topical Solution 10% brought by Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland LTD.
Report Shows Life Science Companies Continue to Be a Favorite Target of Securities Fraud Class Ac...
2/8/2019Despite a decline over the past year of class-action lawsuits, life science companies remain a popular target for securities fraud litigation.
The Company anticipates launching the product this month.
This expected payment is the result of RPI's contingent payments for Tysabri® exceeding $333 million in calendar 2018.
Perrigo Company plc (NYSE, TASE: PRGO) today announced that James Dillard has been appointed Executive Vice President and Chief Scientific Officer.
RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) securities between November 8, 2018 and December 21, 2018, inclusive
Perrigo Company plc announced that President and CEO Murray Kessler will present at the 37th Annual J.P. Morgan Global Healthcare Conference at 5:00 PM EST on Tuesday, January 8, 2019 at the Westin St. Francis Hotel in San Francisco, California
Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Topicort® (desoximetasone)Topical Spray 0.25%
Terms of the settlement are confidential.
Solaraze® Gel, 3% is indicated for the topical treatment of actinic keratoses.
Perrigo Announces Tentative FDA Approval For The First To File Generic Version Of Ultravate® Lotion 0.05%
Perrigo Company (NYSE; TASE: PRGO) today announced it has received tentative approval from the Food and Drug Administration (FDA) for the first to file generic version of Ultravate® Lotion (halobetasol propionate) 0.05%.
This action formally initiates the litigation process under the Hatch-Waxman Act.
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Adapt Pharma Operations Limited, Adapt Pharma Inc., Adapt Pharma Ltd. and Opiant Pharmaceuticals initiated patent litigation on October 25, 2018 in the United States District Court for the District of New Jersey regarding Perrigo's Paragraph IV Abbreviated New Drug Application for naloxone hydrochloride nasal spray 4mg,
Perrigo Company plc today announced that it will release its third quarter calendar year 2018 financial results on Thursday, November 8, 2018. The Company will host a conference call beginning at 8:30 a.m. (EST).
Perrigo Company plc) today announced the launch of an AB-rated generic version of Androgel® Topical Gel.
Perrigo Appoints Murray S. Kessler As President And Chief Executive Officer In Line With Shift To Consumer-Focused Strategy
Murray S. Kessler, former Chief Executive Officer and President at the Lorillard Tobacco Company, appointed President, CEO and member of the Board of Directors effective immediately
Perrigo Company plc today announced that, Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland LTD., Dow Pharmaceuticals Sciences, Inc., and Kaken Pharmaceuticals Co., LTD, initiated patent litigation on September 21, 2018 in the United States District Court for the District
Perrigo Company (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Picato® (ingenol mebutate) gel, 0.015%, 0.05% brought by LEO Pharma Inc., LEO Pharma A/S, and LEO Laboratories Limited.